Mankind Pharma Limited IPO Detail
Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market ("IPM"). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
Company Promoters
Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust and Prem Sheetal Family TrustIPO Details
| IPO Opening Date | Apr 25, 2023 |
| IPO Closing Date | Apr 27, 2023 |
| Issue Type | Book Built Issue IPO |
| Face Value | ₹1 per equity share |
| IPO Price | ₹1026 - 1080 per equity share |
| Market Lot | 13 Shares |
| Min Order Quantity | 13 Shares |
| Listing At | BSE, NSE |
| Issue Size | ₹4,326.36 Cr |
| Fresh Issue | - |
| Offer for Sale | ₹4,326.36 Cr |
| Retail Portion | 35% |
IPO Subscription (Bidding Detail)
| AS On | QIB | SHNI | BHNI | NII | RII | TOTAL |
|---|---|---|---|---|---|---|
| Day 1 | 0.08x | - | - | 0.33x | 0.11x | 0.15x |
| Day 2 | 1.86x | - | - | 1.02x | 0.25x | 0.88x |
| Day 3 | 49.16x | - | - | 3.80x | 0.92x | 15.32x |
IPO Tentative Timetable
The Mankind Pharma Limited IPO open date is Apr 25, 2023, and the close date is Apr 27, 2023. The issue may list on May 09, 2023.
| IPO Open Date | Apr 25, 2023 |
| IPO Close Date | Apr 27, 2023 |
| Basis of Allotment Date | May 03, 2023 |
| Initiation of Refunds | May 04, 2023 |
| Credit of Shares to Demat Account | May 05, 2023 |
| IPO Listing Date | May 09, 2023 |
IPO Lot Size
The Mankind Pharma Limited IPO market lot size is 13 shares. A retail-individual investor can apply for up to 14 lots (182 shares or ₹196560).
| Application | Lots | Shares | Amount (Cut-off) |
|---|---|---|---|
| Minimum | 1 | 13 | ₹14040 |
| Maximum | 14 | 182 | ₹196560 |
IPO Promoter Holding
| Pre Issue Share Holding | 79.00% |
| Post Issue Share Holding |
Company Financials:
For the year/period ended (₹ in Cr.)
| Financial Year | Total Assets | Total Revenue | Profit After Tax |
|---|---|---|---|
| 31-Mar-20 | 5,073.29 | 5,975.65 | 1,056.15 |
| 31-Mar-21 | 6,372.63 | 6,385.38 | 1,293.03 |
| 31-Mar-22 | 9,147.74 | 7,977.58 | 1,452.96 |
| 31-Dec-22 | 9,273.75 | 6,777.82 | 1,015.98 |
Objects of the Issue:
All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.Mankind Pharma Limited IPO Registrar:
KFin Technologies Limited
Mankind Pharma Limited IPO Lead Manager(s):
Kotak Mahindra Capital Company Limited Axis Capital Limited IIFL Securities Ltd Jefferies India Private Limited J.P. Morgan India Private Limited
Company Contact Information:
Mankind Pharma Limited
208, Okhla Industrial Estate
Phase-III,
New Delhi 110020
